Trial Profile
A PHASE IIA PROSPECTIVE, OPEN-LABEL, MULTICENTER STUDY TO DETERMINE THE PHARMACOKINETICS (PK) AND SAFETY AND TOLERABILITY OF AZTREONAM-AVIBACTAM (ATM-AVI) FOR THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAIS) IN HOSPITALIZED ADULTS
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Avibactam/aztreonam (Primary) ; Metronidazole (Primary)
- Indications Intra-abdominal infections
- Focus Adverse reactions; Pharmacokinetics
- Acronyms REJUVENATE
- Sponsors AstraZeneca; Pfizer
- 12 Dec 2019 Results of pharmacokinetics and safety of aztreonam/avibactam for the treatment of complicated intra-abdominal infections in hospitalized adults has published in the Journal of Antimicrobial Chemotherapy.
- 16 Apr 2019 Results (n=34) presented at the 29th European Congress of Clinical Microbiology and Infectious Diseases
- 13 Nov 2017 Status changed from recruiting to completed.